Department of Burn and Plastic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Surgery, Soochow University, Suzhou, China.
J Cell Mol Med. 2020 Oct;24(19):11613-11618. doi: 10.1111/jcmm.15822. Epub 2020 Sep 1.
Skin cutaneous melanoma (SKCM) is a multifactorial disease that presents a poor prognosis due to its rapid progression towards metastasis. This study focused on the identification of prognostic differentially expressed genes (DEGs) between primary and metastatic SKCM. DEGs were obtained using three chip data sets from the Gene Expression Omnibus database. The protein-protein interaction network was described by STRING and Cytoscape. Kaplan-Meier curves were implemented to evaluate survival benefits within distinct groups. A total of 258 DEGs were distinguished as possible candidate biomarkers. Besides, survival curves indicated that DSG3, DSC3, PKP1, EVPL, IVL, FLG, SPRR1A and SPRR1B were of significant value to predict the metastatic transformation of melanoma. To further validate our hypotheses, functional enrichment and significant pathways of the hub genes were performed to indicate that the most involved considerable path. In summary, this study identified substantial DEGs participating in melanoma metastasis. DGS3, DSC3, PKP1, EVPL, IVL, FLG, SPRR1A and SPRR1B may be considered as new biomarkers in the therapeutics of metastatic melanoma, which might help us predict the potential metastatic capability of SKCM patients, thus provide earlier precautionary treatments. However, further experiments are still required to support the specific mechanisms of these hub genes.
皮肤皮肤黑色素瘤(SKCM)是一种多因素疾病,由于其快速进展为转移,预后不良。本研究旨在鉴定原发性和转移性 SKCM 之间的预后差异表达基因(DEGs)。使用来自基因表达综合数据库的三个芯片数据集获得 DEGs。通过 STRING 和 Cytoscape 描述蛋白质-蛋白质相互作用网络。实施 Kaplan-Meier 曲线以评估不同组内的生存获益。总共确定了 258 个 DEG 作为可能的候选生物标志物。此外,生存曲线表明 DSG3、DSC3、PKP1、EVPL、IVL、FLG、SPRR1A 和 SPRR1B 对预测黑色素瘤的转移转化具有重要价值。为了进一步验证我们的假设,对枢纽基因进行了功能富集和显著途径分析,以表明最涉及的重要途径。总之,本研究鉴定了大量参与黑色素瘤转移的 DEGs。DSG3、DSC3、PKP1、EVPL、IVL、FLG、SPRR1A 和 SPRR1B 可以被认为是转移性黑色素瘤治疗的新生物标志物,这可能有助于我们预测 SKCM 患者的潜在转移能力,从而提供早期预防治疗。然而,仍需要进一步的实验来支持这些枢纽基因的具体机制。